Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer Herbst RS; Oh Y; Wagle A; Lahn MClin Cancer Res 2007[Aug]; 13 (15 Pt 2): s4641-6Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through protein kinase C (PKC)-beta and the phosphatidylinositol 3-kinase/AKT pathway to induce tumor cell apoptosis, reduce proliferation, and suppress tumor-induced angiogenesis. In contrast to previous PKC inhibitors, enzastaurin is very well tolerated with a favorable safety profile, allowing it to be dosed for extended durations. In the present review, we summarize the rationale for targeting PKC in cancer, the preclinical experience of enzastaurin, and the clinical findings of the current phase I and II studies. Based on the combined information, we present the rationale for its future assessment in the treatment of lung cancer.|Animals[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Carcinoma, Non-Small-Cell Lung/*drug therapy[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Indoles/*therapeutic use[MESH]|Lung Neoplasms/*drug therapy[MESH]|Protein Kinase C beta[MESH]|Protein Kinase C/*antagonists & inhibitors/drug effects[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH] |